Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

Claudio Soto

Serono Pharmaceutical Research Institute

Geneva

Switzerland

Name/email consistency: high

Serono Pharmaceutical Research Institute, Geneva, Switzerland. 2000 - 2003
Serono International SA, Geneva, Switzerland. 2002
Serono Pharmaceutical Research Institute, 14 Chemin des Aulx, 1228 Plan les Ouates, Geneva, Switzerland. 2001
University of Chile Dept of Biology, Faculty of Sciences, Las Palmeras 3425, Santiago, Chile. 1999

Unfolding the role of protein misfolding in neurodegenerative diseases. Soto, C. Nat. Rev. Neurosci. (2003) [Pubmed]
Cyclic amplification of protein misfolding: application to prion-related disorders and beyond. Soto, C., Saborio, G.P., Anderes, L. Trends Neurosci. (2002) [Pubmed]
Altering prion replication for therapy and diagnosis of transmissible spongiform encephalopathies. Soto, C. Biochem. Soc. Trans. (2002) [Pubmed]
Prions: disease propagation and disease therapy by conformational transmission. Soto, C., Saborío, G.P. Trends. Mol. Med (2001) [Pubmed]
Protein misfolding and disease; protein refolding and therapy. Soto, C. FEBS Lett. (2001) [Pubmed]
Inhibiting the conversion of soluble amyloid-beta peptide into abnormally folded amyloidogenic intermediates: relevance for Alzheimer's disease therapy. Soto, C., Saborio, G.P., Permanne, B. Acta Neurol. Scand., Suppl. (2000) [Pubmed]
Plaque busters: strategies to inhibit amyloid formation in Alzheimer's disease. Soto, C. Mol. Med. Today (1999) [Pubmed]